hereditary colon tumors usually part of different syndromes that require management of both diseases intestinal and extra-intestinal. polyposis syndrome include: Familial adenomatous polyposis, MUTYH associated polyposis, serrated polyposis syndrome, Peutz-Jeghers syndrome, Juvenile polyposis syndrome and syndrome PTEN-hamartomatous. Of all colorectal cancer (CRC), 5% -10% will be caused by hereditary CRC syndrome underlying. Diagnosis and management of polyposis syndromes continues to evolve as new scientific and technological advances are made in relation to identifying the causative gene and increased sophistication of endoscopic therapy for treating polyps.
This, in addition to the data generated from the meticulous recording by registrants polyposis has helped to guide management in what is otherwise a relatively rare condition. These data help guide clinical management of patients and ‘at risk’ families. Diagnosis is either genetic where possible but clinical recognition is key in the absence of the causative gene is identified. In addition, some may overlap syndrome can complicate diagnosis supplementary.
The purpose of the first polyposis management principles to manage and treat the patient presents and then identify ‘at risk’ patients, through screening and predictive genetic testing, to allow therapeutic endoscopic surveillance and guiding surgical prophylaxis. Because of the complexity of the diagnosis and management of patients and their families should be referred to a genetics center or polyposis registry where specific management can occur.
Practical management of polyposis syndromes.
Index disabled children a voice: Translation, transculturalization and validation for Argentine Spanish.
Voice disorders are very common in the pediatric population, with 6% and 23% of all children experience some form of dysphonia [1,2]. Over the years, patients have been diagnosed. There has been increasing awareness and interest in the study of sound changes in children, and most importantly, its impact in their quality of life.
To do this, the instrument is capable of measuring the quality of life in pediatric patients with vocal pathology is required, which can be widely used in the scientific community. The aim of our study was to carry out the translation, and validation transculturalization pVHI (Pediatric Voice Handicap Index) for the study of Argentine Spanish-speakers.A conducted at Hospital de Pediatria Dr. JP Garrahan in Buenos Aires, Argentina.
It included patients aged between 3 and 18 years. The pVHI translated and transculturalized for populations words and validation, the survey was conducted on two groups of patients: one group may be the children against the background of both the surgical laryngeal reconstruction, and dysphonia (n = 35) and being another group of control patients without pathology sound (n = 35). The survey was conducted among the parents or caregivers of children in question.
A significant differences were found between the two groups, both for pVHI overall score and score survey subgroups (p <0.001) with the optimal internal confidence and good Cronbach Alpha for each of subgroups (functional 0.92; organic and emotional 0.87 0.88). Test-retest reliability revealed for “p-value” with no significant differences (p> 0.05) for each of all subgroups (functional 0.68; organic and emotional 0.32 to 0.72) .the validation and transculturalization of the level of disturbance to residents of Argentina pediatric vocal Spain presented an adequate reliability and validity.
Description: A polyclonal antibody for detection of JIP-2 from Human, Mouse, Rat. This JIP-2 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human JIP-2 at AA rangle: 550-630
Description: A polyclonal antibody for detection of JIP-2 from Human, Mouse, Rat. This JIP-2 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human JIP-2 at AA rangle: 550-630
Description: A polyclonal antibody for detection of JIP-2 from Human, Mouse, Rat. This JIP-2 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human JIP-2 at AA rangle: 550-630
Description: A polyclonal antibody for detection of JIP-1 from Human, Mouse, Rat. This JIP-1 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human JIP-1 around the non-phosphorylation site of T103
Description: A polyclonal antibody for detection of JIP-1 from Human, Mouse, Rat. This JIP-1 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human JIP-1 around the non-phosphorylation site of T103
Description: A polyclonal antibody for detection of JIP-1 from Human, Mouse, Rat. This JIP-1 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human JIP-1 around the non-phosphorylation site of T103
Description: A polyclonal antibody for detection of JIP-1 phospho Thr103) from Human, Mouse, Rat. This JIP-1 phospho Thr103) antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human JIP-1 around the phosphorylation site of T103
Description: A polyclonal antibody for detection of JIP-1 phospho Thr103) from Human, Mouse, Rat. This JIP-1 phospho Thr103) antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human JIP-1 around the phosphorylation site of T103
Description: A polyclonal antibody for detection of JIP-1 phospho Thr103) from Human, Mouse, Rat. This JIP-1 phospho Thr103) antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human JIP-1 around the phosphorylation site of T103
Description: A Rabbit Polyclonal antibody against JIP-1 (phospho Thr103) from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, IF, WB, ELISA
Description: A Rabbit Polyclonal antibody against JIP-1 (phospho Thr103) from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, IF, WB, ELISA
Description: Interleukin-3 Human Recombinant produced in E.Coli is single, a non-glycosylated, Polypeptide chain containing 154 amino acids fragment (20-152) and having a total molecular mass of 17.3kDa and fused with a 20 aa N-terminal His tag. ;The IL3 His is purified by proprietary chromatographic techniques.
Description: TGFB3 Human Recombinant produced in plant is a disulfide-linked homodimeric, glycosylated, polypeptide chain containing 118 amino acids and having a molecular mass of 27.2kDa. ;The TGFB3 is fused to 6xHis tag at N-terminus and purified by standard chromatographic techniques.
Description: Can be used for various proteomics studies in both normal and pathological cases. It is an excellent control and suitable for educational purposes. This product is prepared from whole tissue homogenates and has undergone SDS-PAGE quality control analysis. The protein is stored in a buffer with protease inhibitor cocktail fo prevent degradation.
Description: Matrix metalloproteinases (MMPs) are a family of endoproteases that require zinc and calcium for expressing catalytic activity. These enzymes play a central role in the maintenance and remodeling of the extracellular matrix. Elevated expression of their activity, caused either by up-regulation of their expression or down-regulation of their cognate inhibitors, has been implicated in various degenerative disorders, including arthritis, cardiovascular disease, skeletal growth-plate disorders, and cancer metastasis. MMP-3 degrades fibronectin, laminin, collagens III, IV, and X, and cartilage proteoglycans. Recombinant human MMP-3 is a 42.8 kDa protein containing the entire catalytic N-terminal domain and the C-terminal domain (378 amino acids).
Description: PLGF3 Human Recombinant produced in Spodoptera frugiperda is a glycosylated homodimer containing 2 chains of 203 amino acids (Leu19-Arg221) and having a molecular mass of 58kDa.;The PLGF-3 is purified by proprietary chromatographic techniques.
Description: Mouse Monoclonal Trap1 Antibody. Validated in IF, WB and tested in Human, Mouse, Rat.
×
The rate of decline of vocal child is identified through this simple and practical survey, offer additional information about the child vowel perception by the part of the caregiver. We recommend this survey are included as a valuable tool in the evaluation of dysphonia Spanish-speaking children in the family.
